×

Get the Free Prostate Cancer Patient Guide. Enter your email to get the pdf.

Please leave this field empty

Go here to learn more or to get a mailed copy.

12/01/2016

Top Stories of 2016: #5 Protein Discovery Offers New Hope for Lethal Prostate Cancer

Identifying the new “weak spots” in the “soft underbelly” of the most aggressive forms of prostate cancer is the ultimate PCF R+D finding. In 2016, two PCF research teams of over 50 scientists studying a protein called N-Myc, found a major vulnerable new drug target. They found this new weak. Read More

10/24/2016

Young Investigator Award-Class of 2016

The PCF Young Investigator Award-Class of 2016 recipients are: 2016 Elliot Abramowitz–PCF Young Investigator Award Rohit Bose, MD, PhD Memorial Sloan Kettering Cancer Center Mentor: Charles Sawyers, MD Proposal Title: Epigenetic Sensitization of Enzalutamide Response Description The androgen receptor (AR) is the primary driver of prostate cancer, and targeting AR is. Read More

10/24/2016

Creativity Awards Recipients 2011

A rigorous peer review process vetted the 14 selected projects from a field of more than 200 applications representing leading institutions in 11 countries. Historically, 70 percent of such PCF awards have gone on to attract additional multi-year funding from PCF and other sources. These two-year awards are designed to support new. Read More

10/24/2016

Creativity Awards Recipients 2009

Following a rigorous peer review process, PCF selected 10 Creativity Award recipients from more than 300 applications representing 105 institutions in 11 countries. The projects represent a range of research areas, from biomarkers for earlier and more precise detection and treatment to the development of new, nano-enabled therapeutics for metastases.. Read More

10/24/2016

Challenge Awards-Class of 2016

2016-2018 Movember Foundation-PCF Challenge Award ($1 Million) Principal Investigators: Andrew Hsieh, MD (Fred Hutchinson Cancer Research Center), Yu Chen, MD, PhD (Memorial Sloan Kettering Cancer Center), Brett Carver, MD, PhD (Memorial Sloan Kettering Cancer Center) Co-investigators: Peter Nelson, MD (Fred Hutchinson Cancer Research Center), Dana Rathkopf, MD (Memorial Sloan Kettering. Read More

10/13/2016

New Clinical Trial Methods Accelerate Research and Development

Prostate cancer can be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney, will cut the time required to assess new therapies for aggressive. Read More

10/06/2016

Progress Report: Andrea Harzstark, MD

Investigator: Andrea Harzstark, MD – Assistant Professor, University of California, San Francisco Tobacco and Prostate Cancer Therapy: The Missing Link? Prostate cancer affects one in every six American men; ~25% of those men are smokers. Smoking causes many health risks, including a higher risk for lung cancer. Many of the. Read More

10/06/2016

Progress Report: Thomas Guzzo, MD, MPH

Investigator: Thomas Guzzo, MD, MPH – Assistant Professor, University of Pennsylvania Reducing Morbidity from Surgery and Physician Counseling of Treatment Costs Dr. Guzzo has had a very prolific second year as a PCF Young Investigator as evidenced by his publication of ten scientific and clinical reports. His primary research aims. Read More

10/06/2016

Progress Report: Steven Frank, MD

Investigator: Steven Frank, MD– Assistant Professor, University of Texas, M.D. Anderson Cancer Center C4 and MRI-based Prostate Brachytherapy Brachytherapy is a form of radiotherapy where a radiation source, called “seeds”, is precisely implanted into the prostate such that emitted radiation will abolish the tumor. Recent technological advances have increased the. Read More

10/06/2016

Progress Report: Adam S. Feldman, MD, MPH

Investigator: Adam S. Feldman, MD, MPH–Assistant Professor of Surgery, Massachusetts General Hospital, Harvard School of Medicine Active Surveillance: Identifying When to Treat and When Not to Treat In 2010 nearly 218,000 men will be diagnosed with prostate cancer in the United States. However, ~50% of those men will have low. Read More